Case reports show ruxolitinib restored neutrophil counts in patients with T-large granular lymphocyte leukemia and chronic idiopathic neutropenia, suggesting its potential as a treatment.
We describe two cases of severe refractory immune neutropenia: One with T-large granular lymphocyte leukemia and one with chronic idiopathic neutropenia. The JAK inhibitor ruxoltinib restored normal neutrophil counts and was well tolerated in both cases. Further investigation of ruxolitinib as a treatment for immune neutropenia is warranted.
No takes yet. Share an insight, caveat, or question.
Schwarzkopf et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: